On August 24, 2026, GSK PLC (NYSE: GSK) announced that the FDA has accepted its supplemental Biologics License Application for Jemperli (dostarlimab) for priority review in previously untreated stage II/III dMMR/MSI-H locally advanced rectal cancer. The FDA has set a PDUFA action date for February 2027, with the application eligible for expedited review under the National Priority Voucher program.
GSK offers a dividend yield of 3.47% with a payout ratio of 57%, though dividend growth has declined by 5.7% over the past three years, suggesting a stable but cautious income profile supported by a modestly overvalued stock price per the GF Value™ metric. The company holds a respectable GF Score™ of 73/100, reflecting solid profitability and financial health despite moderate growth and momentum challenges. GuruFocus data shows 16 premium gurus currently hold GSK, with 11 trimming positions and 6 adding recently, highlighting mixed but meaningful institutional interest; insider buying and selling activity is notably absent.What’s Behind the News?
GSK’s recent FDA announcement marks a significant milestone in its oncology portfolio expansion. The FDA’s acceptance of the supplemental Biologics License Application for Jemperli, an immunotherapy drug, targets a specific subset of rectal cancer patients characterized by deficient mismatch repair (dMMR) or microsatellite instability-high (MSI-H) tumors. The priority review status and potential accelerated decision under the National Priority Voucher program underscore the promising clinical data from the AZUR-1 trial, where a durable clinical complete response was observed over 12 months. This development could enhance GSK’s competitive positioning in the lucrative oncology market segment.
GSK PLC is a major player in the healthcare sector, specifically within the drug manufacturing industry. With a market capitalization of $104.97 billion, GSK operates globally, producing pharmaceuticals across respiratory, antiviral, vaccine, oncology, and immunology therapeutic classes. The company’s diversified portfolio and strategic joint ventures, particularly in HIV markets, provide a broad revenue base and growth avenues.
Is GSK’s Dividend Safe and Attractive?
GSK currently yields 3.47%, which is attractive relative to many peers in the healthcare sector. The payout ratio stands at 57%, indicating that the company distributes just over half of its earnings as dividends, a level generally considered sustainable. However, the dividend growth rate has contracted by 5.7% over the past three years, signaling some caution regarding future increases. This decline may reflect GSK’s strategic prioritization of reinvestment in R&D and pipeline development, especially in oncology, rather than aggressive dividend hikes. Overall, the dividend appears safe but may not deliver robust growth in the near term.
Supporting this view, the GF Value™ for GSK is $45.49, compared to the current price of $52.41, indicating the stock is modestly overvalued by approximately 15.2%. This valuation suggests that while the dividend yield is appealing, investors are paying a premium relative to intrinsic value estimates based on historical multiples and growth expectations. For those prioritizing dividend income, this valuation context is important to consider alongside yield and payout metrics. More details on GF Value™ can be found here.
What Does GSK’s GF Score™ Tell Us?
The GF Score™ is a composite metric developed by GuruFocus that synthesizes a company’s financial strength, profitability, growth, valuation, and momentum into a single score out of 100. It provides a holistic view of a company’s investment quality. GSK’s GF Score™ of 73 indicates a solid overall profile, with particular strengths in profitability and financial health, though momentum remains a relative weakness.
Metric Rating GF Score™ 73 Financial Strength 5/10 Profitability 8/10 Growth 6/10 Valuation 6/10 Momentum 2/10
GSK’s strongest area is profitability, with an operating margin of 20.7% and net margin of 14.52%, reflecting efficient operations and solid earnings generation. Financial strength is moderate, with an Altman Z-Score in the grey zone (2.11), indicating some financial stress but no immediate bankruptcy risk. Growth metrics are average, while momentum is weak, possibly due to recent stock price volatility and mixed earnings momentum. Investors should weigh these factors when considering GSK’s risk-reward profile. For a detailed breakdown, visit the GSK stock page.
What Are Gurus and Insiders Doing with GSK?
GuruFocus tracks 16 premium gurus holding GSK, with 6 having increased their positions and 11 reducing theirs in recent quarters. This mixed activity suggests some cautious optimism among top investors, balancing the company’s stable dividend and pipeline progress against valuation concerns and growth uncertainties. Insider activity is notably quiet, with no reported insider buying or selling over the past 12 months, which may indicate management’s confidence in the current valuation or a neutral stance on near-term stock movement.
What This Means for Investors
For income-focused investors, GSK presents a relatively safe and attractive dividend yield supported by a moderate payout ratio, despite recent negative dividend growth trends. The stock’s modest overvaluation per GF Value™ and mixed guru ownership signals suggest that while GSK remains a dependable dividend payer, investors should be mindful of valuation risks and limited momentum. The FDA’s acceptance of the Jemperli supplemental application adds a potential catalyst that could enhance future growth prospects. Those prioritizing dividend sustainability and moderate growth may find GSK worthy of consideration, but valuation discipline remains key. More insights and updated data are available on the GSK stock page.
Frequently Asked Questions
What is GSK’s GF Score™?
GSK’s GF Score™ is 73 out of 100, indicating a solid overall financial and operational profile with particular strength in profitability but weaker momentum.
Is GSK’s dividend safe?
Yes, GSK’s dividend appears safe with a 3.47% yield and a payout ratio of 57%, though dividend growth has declined by 5.7% over three years, suggesting limited near-term increases.
What is GSK’s P/E ratio compared to historical?
GSK’s current trailing P/E ratio is 16.26x, slightly above its 5-year median P/E of 14.02x, indicating the stock trades at a modest premium relative to historical earnings multiples.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].